The Symposium, celebrating its 10th year, will allow attendees to revisit the challenges and triumphs of the past decade, while examining the future direction of the field through ground-breaking scientific presentations paired with integrated educational lectures and discussions.
This year’s Meeting will feature the following key studies:
Prostate Cancers
Results from a randomized, double-blind, phase III trial evaluating enzalutamide in men with metastatic castration-resistant prostate cancer who had not previously received chemotherapy (Abstract #LBA1^)
Findings from a Scandinavian Prostate Cancer Group VII trial analyzing 10- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (Abstract #4)
Renal Cell Cancers
A retrospective study investigating the impact of a common hypertension drug on survival rates of patients with metastatic renal cell cancer (Abstract #437)
GU Clinical Trials
A literature review on the early termination of genitourinary cancer clinical trials (Abstract #288)
All clinicians and researchers interested in cutting-edge science and innovation related to the treatment of GU cancers should plan to attend and celebrate ten years of progress.
